chanazone
chanelle pharmaceuticals manufacturing ltd., Īrija - phenilbutazonum - pulveris iekšķīgai lietošanai - 1 g - zirgi
axetine 1,5 g pulveris injekciju/infūziju šķīduma pagatavošanai
medochemie ltd., cyprus - cefuroksīms - pulveris injekciju/infūziju šķīduma pagatavošanai - 1,5 g
axetine 750 mg pulveris injekciju/infūziju šķīduma pagatavošanai
medochemie ltd., cyprus - cefuroksīms - pulveris injekciju/infūziju šķīduma pagatavošanai - 750 mg
influvac suspensija injekcijām
mylan ire healthcare ltd, ireland - gripas vakcīna (virsmas antigēns, inaktivēta) - suspensija injekcijām pilnšļircē
platel 75 mg apvalkotās tabletes
medochemie ltd., cyprus - klopidogrels - apvalkotā tablete - 75 mg
axetine 500 mg apvalkotās tabletes
medochemie ltd., cyprus - cefuroksīms - apvalkotā tablete - 500 mg
klerimed 250 mg apvalkotās tabletes
medochemie ltd., cyprus - klaritromicīns - apvalkotā tablete - 250 mg
klerimed 500 mg apvalkotās tabletes
medochemie ltd., cyprus - klaritromicīns - apvalkotā tablete - 500 mg
axetine 250 mg apvalkotās tabletes
medochemie ltd., cyprus - cefuroksīms - apvalkotā tablete - 250 mg
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - karcinoma, švamšā šūna - antineoplastiski līdzekļi - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.